74 participants
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-12-10
- Start Date:
- 2026-01-01
- Completion:
- 2029-12-31
Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Hyperprogression
Interventions
- COMBINATION_PRODUCT
- DRUG
No Results Yet